Search and analyze individual stocks with comprehensive metrics
Transgene Biotek Ltd
Fundamental Score
Transgene Biotek Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of TRABI across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
13 factors identified
Below-Average Return on Equity (-6.56%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-1.75%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (-411.11%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Profit Decline Concern (-457.14%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-16.67%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Elevated Debt Levels (D/E: 1.79)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Weak Interest Coverage (-1.25x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-0.42 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Low Promoter Commitment (23.64%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High Debt-to-Equity Ratio
Observation: Elevated financial risk due to high leverage.
Analysis: High debt levels may strain cash flows and increase financial risk during economic downturns.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Loading Peer Comparison
Finding companies in the Healthcare Service Provider sector...
Financial Statements
Comprehensive financial data for Transgene Biotek Ltd
About TRABI
Business Overview
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
Company Details
Key Leadership
TRABI Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Transgene Biotek Ltd (TRABI)?
As of 14 Jan 2026, 11:00 am IST, Transgene Biotek Ltd (TRABI) is currently trading at ₹2.77. The stock has a market capitalization of ₹26.14 (Cr).
Is TRABI share price Overvalued or Undervalued?
TRABI is currently trading at a P/E ratio of 0.00x, compared to the industry average of 39.28x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Transgene Biotek Ltd share price?
Key factors influencing TRABI's price include its quarterly earnings growth (Sales Growth: -16.67%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Transgene Biotek Ltd a good stock for long-term investment?
Transgene Biotek Ltd shows a 5-year Profit Growth of 14.15% and an ROE of -6.56%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.79 before investing.
How does Transgene Biotek Ltd compare with its industry peers?
Transgene Biotek Ltd competes with major peers in the Healthcare Service Provider. Investors should compare TRABI's P/E of 0.00x and ROE of -6.56% against the industry averages to determine its competitive standing.
What is the P/E ratio of TRABI and what does it mean?
TRABI has a P/E ratio of N/Ax compared to the industry average of 39.28x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is TRABI performing according to Bull Run's analysis?
TRABI has a Bull Run fundamental score of 0.5/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does TRABI belong to?
TRABI operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Transgene Biotek Ltd.
What is Return on Equity (ROE) and why is it important for TRABI?
TRABI has an ROE of -6.56%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Transgene Biotek Ltd generates profits from shareholders' equity.
How is TRABI's debt-to-equity ratio and what does it indicate?
TRABI has a debt-to-equity ratio of 1.79, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.
What is TRABI's dividend yield and is it a good dividend stock?
TRABI offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has TRABI grown over the past 5 years?
TRABI has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth 14.15%, and EPS Growth 14.15%.
What is the promoter holding in TRABI and why does it matter?
Promoters hold 23.64% of TRABI shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is TRABI's market capitalization category?
TRABI has a market capitalization of ₹26 crores, placing it in the Small-cap category.
How volatile is TRABI stock?
TRABI has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for TRABI?
TRABI has a 52-week high of ₹N/A and low of ₹N/A.
What is TRABI's operating profit margin trend?
TRABI has a 5-year average Operating Profit Margin (OPM) of -411.11%, indicating the company's operational efficiency.
How is TRABI's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -16.67% and YoY Profit Growth of -457.14%.
What is the institutional holding pattern in TRABI?
TRABI has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.